Saturday 17 October 2026
Export EVO’s income statement to Excel — free account
Evotec AG
EVO Healthcare Drug Manufacturers Specialty & Generic
Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
1.38
0.04
−2.82%
Follow EVO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
1.55 | 1.23 | 1.03 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(16.30) | 14.64 | (193.71) | — | |
P/B ratio |
1.38 | 1.19 | 1.08 | — | |
Price to Tangible BV |
2.21 | 1.90 | 1.92 | — | |
EV/Sales |
1.91 | 1.19 | 0.97 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
(416.12) | (102.32) | 45.06 | — | |
EV/FCF |
(14.82) | (10.25) | (12.99) | — | |
Quick Ratio |
1.01 | 1.77 | 1.36 | 1.92 | |
Current Ratio |
2.12 | 2.07 | 1.68 | 2.33 | |
Net Debt/EBITDA |
(3.38) | (0.76) | 1.20 | 0.00 | |
Debt/Assets |
21.87% | 26.18% | 18.22% | 30.23% | |
Debt/Equity |
0.48 | 0.55 | 0.43 | 0.72 | |
Asset Turnover |
0.39 | 0.45 | 0.44 | 0.00 | |
Operating CF/Net income |
1.57 | 4.71 | 0.03 | 0.00 | |
Capex/Depreciation |
0.00 | (0.13) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5.32% | 3.93% | 6.44% | — | |
Selling, General and Administrative Expense of Revenue |
25.82% | 17.66% | 27.95% | — | |
Intangible Assets out of Total Assets |
0.17 | 0.18 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Graham Net Nets |
(0.16) | (0.14) | (0.30) | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(13.73%) | (10.71%) | (25.52%) | — | |
Free Cash Flow Yield |
(8.30%) | (9.47%) | (7.25%) | — | |
Revenue per Share |
0.54 | 0.83 | 0.52 | — | |
Operating CF per Share |
(0.22) | 0.21 | (0.01) | 0.00 | |
Capex per Share |
(0.07) | (0.04) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(0.30) | 0.17 | (0.05) | 0.00 | |
Cash per Share |
0.78 | 1.52 | 1.47 | 0.00 | |
Shareholders Equity per Share |
2.63 | 2.59 | 2.31 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.63 | 2.59 | 2.31 | 0.00 | |
Free Cash Flow |
(105.70) | 59.89 | (17.11) | (137.31) | |
Working Capital |
489.36 | 446.76 | 336.96 | 484.18 | |
Capital Expenditures |
(26.56) | (14.83) | (12.53) | (12.71) | |
Net Current Asset Value |
(209.76) | (155.34) | (267.92) | (208.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.14 | 0.05 | 0.07 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
227.35 | 184.26 | 181.83 | 145.38 | |
Average Payables |
67.35 | 83.05 | 64.42 | 61.47 | |
Average Inventory |
37.89 | 33.42 | 36.95 | 42.04 | |
Average Assets |
2,130.60 | 2,004.34 | 1,984.10 | 1,941.40 | |
Average Common Equity |
1,000.10 | 975.68 | 889.89 | 867.00 |
Columns are period end dates